Table 2.
Markers of oxidative stress in blood of prostate cancer patients and in control group.
| Control | Patients | ||||
|---|---|---|---|---|---|
| Before therapy | After radiotherapy | ||||
| Immediately | 1.5–3 months | 2 years | |||
| SOD (U/g Hb) | 1017.9 ± 253.5 | 1292.7 ± 534.6 | 1377.1 ± 646.1 | 1237.7 ± 542.1 | 789.9 ± 113.3 |
| CAT (104 IU/g Hb) | 58.62 ± 10.04 | 62.48 ± 13.79 | 63.31 ± 16.19 | 61.16 ± 14.2 | 58.1 ± 11.4 |
| GPx (U/g Hb) | 12.2 ± 6.3 | 8.1** ± 3.9 | 6.1** ± 3.1 | 8.5∗a ± 4.2 | 4.8** ± 1.9 |
| TBARSeryth. (nmol MDA/g Hb) | 24.1 ± 8.8 | 43.0** ± 19.7 | 38.5* ± 19.7 | 41.0** ± 16.3 | 29.8 ± 11.4 |
| TBARSplasma (10−2 nmol MDA/mL) | 28.5 ± 8.8 | 44.6** ± 19.7 | 45.7** ± 19.7 | 43.2** ± 16.3 | 46.4* ± 15.6 |
SOD: superoxide dismutase; CAT: catalase; GPx: glutathione peroxidase; TBARSs: thiobarbituric acid reactive substances.
Data expressed as mean ; *P < 0.05; **P < 0.001 compared with control group.
a P < 0.05 immediately after radiotherapy.